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ttp://dx.doi.org/10.1016/j.ajpath.2012.12.020Althoughanti-vascular endothelial growth factor (VEGF) treatments reducepathological neovascularization in
the eye and in tumors, the regression is often not sustainable or is incomplete. We investigated whether
vascular endothelial cells circumventanti-VEGF therapies by activating theunfoldedprotein response (UPR) to
override the classic extracellular VEGF pathway. Exposure of endothelial cells to VEGF, high glucose, or H2O2
up-regulated the X-box binding protein-1/inositol-requiring protein-1 (IRE1) a and activating transcription
factor 6 (ATF6) arms of the UPR compared with untreated cells. This was associated with increased expression
in a-basic crystallin (CRYAB), which has previously bound VEGF. siRNA knockdown or pharmacological
blockade of IRE1a, ATF6, or CRYAB increased intracellular VEGF degradation and decreased full-length
intracellular VEGF. Inhibition of IRE1a, ATF6, or CRYAB resulted in an approximately 40% reduction of
in vitro angiogenesis, which was further reduced in combination with a neutralizing antibody against
extracellular VEGF. Blockade of IRE1a or ATF6 in the oxygen-induced retinopathy or choroidal neo-
vascularization mouse models caused an approximately 35% reduction in angiogenesis. However, combina-
tion therapy of VEGF neutralizing antibody with UPR inhibitors or siRNAs reduced retinal/choroidal
neovascularizationbya further 25%to40%,and this inhibitionwas signiﬁcantly greater thaneither treatment
alone. In conclusion, activation of the UPR sustains angiogenesis by preventing degradation of intracellular
VEGF. The IRE1a/ATF6 arms of the UPR offer a potential therapeutic target in the treatment of pathological
angiogenesis. (Am J Pathol 2013, 182: 1412e1424; http://dx.doi.org/10.1016/j.ajpath.2012.12.020)Supported by the James & Esther King Biomedical Foundation and NIH
grant EY018358 (M.E.B.); NIH grants EY012601, EY007739, DK096221,
and HL10170 (M.B.G.); and Florida Department of Health grant 60-NIR-
09 (L.H.S.).
L.L. and X.Q. contributed equally to this work.It is evident that there exists a plethora of pro- and anti-
angiogenic factors that regulate the ocular vasculature and
inﬂuence the development and progression of aberrant neo-
vascularization, such as in diabetic retinopathy and age-
related macular degeneration (AMD). Furthermore, the
spatiotemporal balance of these pro- and anti-angiogenic
factors is critical in determining whether vascular homeo-
stasis or a pathological condition predominates. The collec-
tive evidence suggests that the vascular endothelial growth
factor (VEGF) family is critical for ocular angiogenesis,1 and
treatment of patients with AMD who have choroidal neo-
vascularization (CNV) using inhibitors of extracellular
VEGF, such as ranibizumab (Lucentis) or bevacizumab
(Avastin), signiﬁcantly reduces CNV.2,3 However, as shown
by the ANCHOR, MARINA, and VISION clinical trials,
regression is often not sustainable or is incomplete and only
approximately 50% of patients beneﬁt signiﬁcantly from thisstigative Pathology.
.therapeutic strategy.4,5 Furthermore, similar limitations are
associated with the use of these anti-VEGF agents in treat-
ment of proliferative diabetic retinopathy and diabetic
macular edema.6 The challenge, therefore, is to ﬁnd an
adjunct to the current therapy that will obviate the repeated
injections, lower the dose of exogenous VEGF blocker, and
act synergistically to elicit complete regression of the
vascular lesion. There is increasing evidence from the cancer
ﬁeld that endothelial cells protect themselves and sustain
tumor angiogenesis by intracellular accumulation of VEGF
and self-regulation through an intracellular pathway.7,8
Table 1 LD50 of Compounds That Inhibit UPR Proteins in Bovine
Microvascular Endothelial Cells
Compounds ID50 (mmol/L) UPR proteins
MG132 75 IRE1a/XBP-1
17-AAG 2 IRE1a
1-NM-PP1 50 IRE1a
AEBSF 1500 ATF6
Lactacystin 35 IRE1a/XBP-1
AEBSF, 4-(2-aminoethyl) benzenesulfonyl ﬂuoride hydrochloride.
Targeting the UPR Boosts VEGF BlockadeEndoplasmic reticulum (ER) stress and the unfolded protein
response (UPR)9,10 play a critical role in transcriptional
regulation of VEGF-A11 and protect VEGF from intracellular
degradation.12 ER stress can activate one or more of the three
ER stress sensors [protein kinase RNA-like endoplasmic
reticulum kinase (PERK), inositol-requiring protein-1
(IRE1), and activating transcription factor 6 (ATF6)], leading
to activation of the UPR pathway and production of chap-
erone proteins.9,10 a-Basic crystallin (CRYAB) is a classic
small heat shock protein that is up-regulated by ER stress and
has interactive sequences for VEGF.13 A strong association
between CRYAB expression and angiogenesis has been
shown. By using CRYAB/ mice, Kase et al14 reported an
attenuation of CNV. Dimberg et al15 showed that tumors in
CRYAB/ mice are signiﬁcantly less vascularized than in
wild-type mice. Based on these observations, we assessed
whether activation of the UPR and downstream CRYAB up-
regulation may sustain the VEGF signaling pathway and if
targeting both extracellular VEGF and the UPR will repre-
sent a more effective strategy than current extracellular
VEGF therapies alone.
Materials and Methods
Cell Culture
Bovine retinal microvascular endothelial cells were isolated
and cultured, as previously described.16 Brieﬂy, freshly
isolated bovine retinas were homogenized, and after trap-
ping on an 83-mm nylon mesh, they were transferred into an
enzyme mixture [500 mg/mL collagenase, 200 mg/mL
protease (Pronase), and DNase] at 37C for 20 minutes. The
resultant vessel fragments were trapped on a 53-mm mesh,
washed, and pelleted, and cells were plated in endothelial
cell basal medium with growth supplement (Invitrogen,
Carlsbad, CA) at 37C, 5% CO2, for 3 days. The cells were
used within three passages.
Activation of the UPR
Retinal microvascular endothelial cells were treated with 100
ng/mL VEGF, 25 mmol/L glucose, or 200 mmol/L H2O2 for
24 hours. The 5.2 mmol/Lmedium alone acted as the baseline
control because 5.2 mmol/L glucose is considered the nor-
moglycemic control for cultured endothelial cells and
hyperglycemia is usually in the range from 15 to 30 mmol/L
glucose. We chose to use 25 mmol/L glucose based on our
previous studies and 25 mmol/L mannitol as an osmotic
control.17 The expression levels of X-box binding protein
(XBP)-1, ATF6, IRE1, PERK, CRYAB, and a-tubulin were
determined by using Western blot analysis.
VEGF ELISA Measurement
Retinal endothelial cells were cultured in 6-well plates. After
24-hour treatmentwith 100 ng/mLVEGF, 25mmol/L glucose,The American Journal of Pathology - ajp.amjpathol.orgor 200 mmol/L H2O2, the cells were rinsed in PBS, and fresh
microvascular endothelial basal medium with 5% fetal calf
serumwas added. After a further 24 hours, the culture medium
was removed and centrifuged at 2000  g for 10 minutes to
remove cellular debris. The cell numbers of each well were
counted before preparing total cell lysates using radio-
immunoprecipitation assay (RIPA) buffer. VEGF concentra-
tions were measured in duplicate in each sample from at least
three separate experiments with a VEGF DuoSet enzyme-
linked immunosorbent assay (ELISA; R&D Systems, Min-
neapolis, MN), according to the manufacturer’s instructions.
The results are expressed as ng/106 cells per day VEGF.
In Vitro LD50 of Potential Pharmacological UPR
Inhibitors
We selected a list of compounds reported to be capable of
inhibiting different UPR pathways (Table 1) and then
measured their cytotoxicity using cultured retinal micro-
vascular endothelial cells. In brief, cells were exposed to
a serial dilution of test compound for 24 hours, and cyto-
toxicity was determined using the Cytotoxicity Detection
Kit (Roche Applied Science, Indianapolis, IN), according to
the manufacturer’s instructions. This kit can detect lactate
dehydrogenase activity released from damaged cells, and
results are presented as the LD50. Vehicle was used as
a baseline control.
siRNA Knockdown of UPR Pathways in Cultured
Endothelial Cells
Two siRNAs were synthesized by Life Technologies
Corporation (Carlsbad, CA) against each of bovine CRYAB,
IRE-1, ATF6, and PERK. The siRNA sequences are shown
in Table 2. Scrambled siRNA acted as a negative control.
Bovine microvascular endothelial cells were seeded in 6-well
tissue culture dishes for 24 hours before transfection with
respective siRNA (30 nmol/L) using siPORT transfection
agent (Life Technologies Corporation, Carlsbad, CA) per the
manufacturer instructions. Knockdown was conﬁrmed by
Western blot analysis.
Western Blot Analysis and Immunoprecipitation
Western blot analysis and immunoprecipitation were per-
formed as previously described.18 In brief, cells were1413
Table 2 Corresponding Silencer siRNA Construction Kit Template Sequences
siRNA Sense primer Antisense primer
IRE1 50-AAGTACCAAATGTCCTGCTTTCCTGTCTC-30 50-AAAAAGCAGGACATTTGGTACCCTGTCTC-30
IRE1 50-AAATGGCGATCATCTTCTCTACCTGTCTC-30 50-AATAGAGAAGATGATCGCCATCCTGTCTC-30
ATF6 50-AAAGTCACGGAAAGTTTTCCACCTGTCTC-30 50-AATGGAAAACTTTCCGTGACTCCTGTCTC-30
ATF6 50-AATCACTCGACCTCCCAACTTCCTGTCTC-30 50-AAAAGTTGGGAGGTCGAGTGACCTGTCTC-30
PERK 50-AATGCCTTCGATGTTGTTGTACCTGTCTC-30 50-AATACAACAACATCGAAGGCACCTGTCTC-30
PERK 50-AACATTGAAGACACCCCTCTTCCTGTCTC-30 50-AAAAGAGGGGTGTCTTCAATGCCTGTCTC-30
CRYAB 50-AAATCCTGGCGCTCTTCATGTCCTGTCTC-30 50-AAACATGAAGAGCGCCAGGATCCTGTCTC-30
CRYAB 50-AAGAATCCGTCAGCTTCAGCACCTGTCTC-30 50-AATGCTGAAGCTGACGGATTCCCTGTCTC-30
Silencer siRNA construction kit (part No. AM1620; Life Technologies Corporation, Carlsbad, CA).
Liu et alwashed with PBS and lysed in RIPA buffer at 4C containing
a cocktail of protease (Sigma-Aldrich, St. Louis, MO) and
phosphatase (RocheAppliedScience) inhibitors for30minutes.
Lysateswere centrifuged, supernatantswere collected, and total
protein concentration was determined by the MicroBCA
reagent assay (Pierce, Rockford, IL).Western blot analysis was
performed after SDS-PAGE (10% gel; equal aliquot of total
proteins per lane) and transfer onto polyvinylidene diﬂuoride
membranes. The IRE1a, ATF6, CRYAB, and VEGF proteins
were detected using an afﬁnity-puriﬁed rabbit or mouse anti-
IRE1a (Sigma-Aldrich), anti-ATF6 (Sigma-Aldrich), anti-
CRYAB (Novus Biologicals, LLC, Littleton, CO), and
anti-VEGF (Sigma-Aldrich), followed by incubation with
polyclonal anti-rabbit in goat or mouse in rabbit horseradish
peroxidaseeconjugated secondary antibodies (Sigma-Aldrich)
at 1:2000 dilution. The proteins were detected and visualized
with the ECL Plus Western Blotting Detection System (GE
Healthcare Biosciences, Pittsburgh, PA), and resultant bands
were normalized against a-tubulin (Sigma-Aldrich). The
intensity of each immunoreactive band was quantiﬁed using
ImageJ software version 1.46 (NIH, Bethesda, MD).18 For
immunoprecipitation, total proteins were immunoprecipitated
with 10 mg of relevant antibodies for 2.5 hours at 4C, followed
by the addition of 20 mL of protein A/G-agarose overnight at
4C. The resultant pellet was dissolved in 2 Laemmli buffer
(Bio-RadLaboratories,Hercules,CA) and subjected toWestern
blot analysis.
In Vitro Tube Formation Assay
In vitro tube formation assays were performed as previously
described.16 Brieﬂy, near-conﬂuent microvascular endothe-
lial cells were pretreated with 100 ng/mL VEGF for 2 hours
and then either treated for 24 hours with test compounds at
serial concentrations, as indicated, or VEGF165 neutralizing
antibody or washed and maintained in basal medium for 24
hours to establish the intracrine VEGF signaling pathway,
before treatment with test compounds or VEGF165
neutralizing antibody (anti-human VEGF165, AB-293-NA;
R&D Systems), which we have previously shown to bind
strongly to bovine VEGF. Cells without VEGF treatment or
with VEGF only were used as control. In addition, siRNA-
treated cells, with or without VEGF, were also assessed. The
cells were then detached and plated at the concentration of14142.5  104 per well on 24-well plates coated with 12.5% (v/v)
growth factorepoor Matrigel (BD, Franklin Lakes, NJ) and
left overnight. The medium was then aspirated, and 250 mL
per well of 12.5% Matrigel was overlaid on the cells for
2 hours to allow the polymerization of Matrigel, followed by
the addition of 500 mL per well of basal medium, MCD131,
with 10% fetal calf serum for 24 hours. The following day,
the culture plates were observed under a phase-contrast
microscope and imaged using ﬁve random ﬁelds (original
magniﬁcation, 10). The tubule length (mm/mm2) per
microscope ﬁeld was quantiﬁed.
VEGF Degradation
VEGF degradation was assessed as previously described.12
Brieﬂy, the cells were trypsinized and pelleted at 2000  g
for 5 minutes. The resultant pellets were dissolved in 500 mL
of denaturing buffer (20 mmol/L Tris-HCl, pH 8.0, 6 mol/L
guanidine-HCl, 5 mmol/L EDTA, and 4 mmol/L dithio-
threitol) at room temperature for 2 hours. Total protein
concentration was estimated by measuring the UV absor-
bance at 280 nm and diluted with denaturing buffer to a ﬁnal
concentration of 1 mg/mL. After centrifugation at 46,000 g
at 4C for 30minutes, the supernatant was concentrated to 100
mL using Millipore Ultrafree centrifugal devices (molecular
weight cutoff, 3.5 kDa) (Millipore, Bedford, MA). The
samples were mixed with 1:2 standard sample buffer and
analyzed by using Western blot analysis using an antibody
against the C-terminal of human VEGF (Abcam, Cambridge,
MA). In accordance with previous studies, the degradation of
VEGF resulted in multiple lower molecular weight bands, of
which a fragment of approximately 38 kDa is prominent.19
Animal Studies
Allmicewere housed under speciﬁc pathogen-free conditions
and handled in accordance with the Association for Research
inVision andOphthalmology statement for Use ofAnimals in
Ophthalmic and Vision Research and the guidelines of the
Institutional Animal Care and Use Committee at the
University of Florida (Gainesville, FL). Two animal models
were used; the oxygen-induced retinopathy (OIR) model,
which is representative of retinal neovascularization, as
occurs in retinopathy of prematurity and diabetic retinopathy,ajp.amjpathol.org - The American Journal of Pathology
Targeting the UPR Boosts VEGF Blockadeand the laser-induced CNV model, which is representative of
aberrant vascular growth in AMD.
OIR Model
For the OIR model, C57BL/6 mouse pups were exposed to
75% oxygen from postnatal day 7 (P7) to P12, along with
nursing mothers.20 On day P12, the pups were removed from
high oxygen conditions, and on P17, mice were sacriﬁced.
Eyeswereﬁxed in paraformaldehyde, parafﬁn embeddingwas
performed, and serial sections (5 mm thick) were obtained.
Representative sections (every 30th section) across the retina
were stained with H&E to visualize retinal structure and note
any overt toxicity. A masked investigator counted all endo-
thelial cell nuclei above the internal limiting membrane in all
representative sections through each eye. Vascular cell nuclei
are considered to be associated with neovascularization if they
are on the vitreous side of the internal limiting membrane and
the region of the optic nerve is not considered. The data pre-
sented represent random sampling from aminimumof 12 pups
per treatment group. Efﬁcacy of treatment was calculated as
the percentage average nuclei per section in the eyes treated
with test agent compared with vehicle control.
CNV Model
The laser procedurewas undertaken as previously described.21
Brieﬂy, 8-week-old female C57BL/6 mice were anesthetized
with a mixture of 80 mg/kg ketamine and 10 mg/kg xylazine,
and their pupils were dilated with 0.5% tropicamide and 2.5%
phenylephrine. Under the fundus microscope, an argon green
ophthalmic laser, coupled to a slit lamp set to deliver a 50-
millisecond pulse at 200 mW, with a 50-mm spot size, was
used to rupture theBruch’smembrane in three quadrants of the
right eye, located approximately 50 mm from the optic disk at
relative positions of 9 AM, 12 PM, and 3 PM. The left eye
served as an untreated control. Mice were sacriﬁced 14 days
after laser injury, and the eyes were enucleated. Formeasuring
lesion volume, we used a vascular-speciﬁc dye, Ricinus
Communis Agglutinin I conjugated to rhodamine, to label
whole ﬂat mounts of retinal pigment epithelium (RPE)/
choroid/sclera. The laser lesions were then imaged by Z-series
laser scanning confocal microscopy to obtain lesion volume
using ImageJ software version 1.46. In all CNV studies,
animalswere randomized and treatmentswere blinded until all
analysis was complete. All determinations were performed in
at least six animals per group. In addition, gross retinal/
choroidal structure and vascular patterns were examined for
possible adverse effects of the test compound or vehicle.
Treatment Regimen
Mice received an intravitreal injection in the left eye of 0.5
mL in the OIR model and 1.0 mL in the CNV model while
the right eye acted as the uninjected control. Groups of six
animals received the following treatments.The American Journal of Pathology - ajp.amjpathol.orgsiRNA Treatment
Ambion in Vivo siRNAs predesigned and prevalidated for
targeting murine CRYAB (s64457), IRE1 (s95857), ATF6
(s105469), and scrambled were purchased from Life Tech-
nologies Corporation. These siRNAs incorporated additional
chemical modiﬁcations for superior serum stability with
in vivo applications and reduced susceptibility to degradation
by ribonucleases. All siRNAs were 19mer to avoid the
potential anti-angiogenic effect of 21mer or longer siRNAs
acting via toll-like receptor 3.22 As previously determined, 1
and 2 mg per eye siRNAwas delivered intravitreally at P12 in
the OIR model or the time of laser injury in the CNV model.
UPR Pathway Inhibitor Treatment
A total of 5 mmol/L of potential UPR pathway inhibitor,
MG132, and 50 mmol/L 4-(2-Aminoethyl) benzenesulfonyl
ﬂuoride hydrochloride (AEBSF) were delivered intra-
vitreally at P12 in the OIR model or the time of laser injury
in the CNV model. Saline or dimethyl sulfoxide vehicle
controls were also included.
VEGF164 Neutralizing Antibody Treatment
A total of 5 ng per eye VEGF164 neutralizing antibody (anti-
mouse VEGF164, AF-493-NA; R&D Systems) was delivered
intravitreally at P12 in theOIRmodel or the time of laser injury
in theCNVmodel. In some studies, the antibodywas alsogiven
at 7 days after laser injury. Vehicle and 5 ng per eye of the
appropriate Fc fragment (Jackson Immunoresearch, West
Grove, PA) were included as controls.
Combined Treatment
For combination therapy, 5 ng per eye of VEGF164 neutral-
izing antibody was delivered intravitreally, together with
siRNA or UPR inhibitor at P12 in the OIR model or the time of
laser injury in the CNV model. In some studies, the antibody
was also given at 7 days after laser injury.
Conﬁrmation of siRNA Knockdown
For PCR assessment, 6-week-old female C57BL/6J mice
received an intravitreal injection of 2 mg/mL siRNA at laser
injury in the CNV model into the left eye, whereas the right
eye served as an uninjected control. All siRNAs were as
previously described. Mice were sacriﬁced at 2 days after
treatment, eyes were enucleated, and the retina plus RPE/
choroid were isolated. Total RNA was extracted with TRIzol
total RNA isolation reagent (Invitrogen) and quantiﬁed using
a Nanodrop Spectrophotometer (NanoDrop Products, Wil-
mington, DE). cDNA was synthesized from 1 mg total RNA
from each sample using the iScript cDNA Synthesis Kit (Bio-
Rad, Hercules, CA). cDNA at 1:10 dilution was used for
quantitativeRT-PCR (RT-qPCR) on aBioRadC1000Thermal
Cycler. mRNA expression was assessed using the RT2 qPCR
Primer Assay from Qiagen (Valencia, CA), with the following
primers: mouse Ern1 (PPM36937A-200), mouse Cryab
(PPM03570F-200), and mouse Atf6 (PPM33057A-200).1415
Liu et alFinal expression was normalized to the housekeeping gene,
glyceraldehyde-3-phosphate dehydrogenase (GAPDH): RT2
qPCR Primer Assay for mouse GAPDH (PPM02946E-200).
Relative transcript abundance was determined by using the1416DDCT or DCT method after normalization with GAPDH. All
samples were run in triplicate. Error bars represent SEM.
For immunohistochemistry (IHC), 6-week-old female
C57BL/6J mice received an intravitreal injection of 2 mg/mL
siRNA at laser injury and were sacriﬁced at 14 days after
treatment. Eyes were enucleated, and the RPE/choroid/sclera
were prepared and then blocked with 10% normal goat sera,
plus 1% bovine serum albumin for 2 hours at room tempera-
ture. Mouse monoclonal anti-CRYAB, anti-ATF6, and rabbit
polyclonal anti-IRE1 (Lifespan Biosciences, Seattle, WA)
were diluted 1:50 and 1:200, respectively, in PBS with 1%
normal goat sera plus 1% bovine serum albumin and incubated
overnight at 4C. Tissues received a secondary antibody
conjugated with ﬂuorescein isothiocyanate in 1:600 for 1 hour
at room temperature in the dark. To visualize vessels, we used
a vascular-speciﬁc dye, Ricinus Communis Agglutinin I,
conjugated to tetramethylrhodamine isothiocyanate (TRITC),
to label the whole ﬂat mounts of RPE/choroid, which were
incubated for 30 minutes at room temperature in 1:400 of 10
mmol/L HEPES, 150 mmol/L NaCl, and 0.1% Tween 20. The
tissues were covered in aqueous VectaShield mounting
medium (Vector Laboratories, Inc., Burlingame, CA) for
observation on an Olympus DSU-Olympus IX81 confocal
microscope (Olympus America, Inc., Center Valley, PA).
Statistical Analysis
All experiments were repeated at least three times. Results are
expressed as means SEM. The Mann-Whitney test was used
to determine statistical signiﬁcance of the densitometry data of
Western blot analysis. An unpaired two-tailed Student’s t-test
was performed for the signiﬁcance of the results of ELISA,
in vitro tubule formation assay, in vivo CNV, and OIR models.
Statistical analysis was performed using Prism 5 version 5.01
(GraphPad Software, Inc., La Jolla, CA) with P < 0.05
considered statistically signiﬁcant.
Results
Induction of ER Stress and CRYAB Up-Regulation
It has previously been reported that growth factors, hypergly-
cemia, and oxidative stress can activate the ER stress
response.9,10 Western blot analysis demonstrated that exposureFigure 1 The effect of cellular stress on the UPR pathways and CRYAB
expression. Conﬂuent retinal microvascular endothelial cells were treated with
100 ng/mL VEGF, 25 mmol/L glucose, or 200 mmol/L H2O2 for 24 hours. Cells
treated with 5.2 mmol/L glucose containing medium alone acted as a negative
control (unstimulated). Cell lysates were prepared in RIPA buffer, and samples
were assessed by using Western blot analysis for XBP-1 (processed and
unprocessed), ATF6, IRE1a, PERK, and CRYAB. a-Tubulin served as the loading
control. A: Representative Western blot analysis. B: Quantitation of Western
blot analyses from a minimum of three separate experiments presented as the
relative ratio to the tubulin loading control. C: Comparison of ATF6, IRE1a,
XBP-1, PERK, and CRYAB protein expression in cells exposed to 25 mmol/L
glucose or 25 mmol/L mannitol, determined by quantitation of Western blot
analyses from a minimum of three separate experiments presented as the
relative ratio of CRYAB to the tubulin loading control. *P < 0.05.
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Figure 2 The effect of siRNA knockdown of the
UPR pathways on CRYAB expression. Conﬂuent
retinal microvascular endothelial cells were treated
with 100 ng/mL VEGF, 25 mmol/L glucose, or 200
mmol/L H2O2 for 24 hours in the presence of 30
nmol/L IRE1a, ATF6, or PERK siRNA. Cells treated
with 5.2 mmol/L glucose containing medium alone
or exposed to scrambled siRNA (scr) acted as
negative controls. Cell lysates were prepared in
RIPA buffer, and samples were assessed by using
Western blot analysis for XBP-1 (processed and
unprocessed), ATF6, IRE1a, PERK, and CRYAB.
a-Tubulin served as the loading control. A:
Conﬁrmation that siRNA treatment resulted in the
knockdown of CRYAB, IRE1a, ATF6, or PERK. B:
Representative Western blot analysis. C: Quantita-
tion of Western blot analyses from a minimum of
three separate experiments presented as the rela-
tive ratio to the tubulin loading control. Compar-
ison of CRYAB protein expression in cells exposed
to 25 mmol/L glucose or 25 mmol/L mannitol,
determined by quantitation of Western blots from
a minimum of three separate experiments pre-
sented as the relative ratio of CRYAB to the tubulin
loading control. *P < 0.05. IB, immunoblot.
Targeting the UPR Boosts VEGF Blockadeof microvascular endothelial cells to VEGF, high glucose, or
H2O2 caused an up-regulation of the XBP-1/IRE1a and ATF6
arms of the UPR; however, no effect was observed on PERK
when compared with untreated control cells (Figure 1, A
and B). A total of 25 mmol/L mannitol, used as an osmotic
control for 25 mmol/L glucose, showed no signiﬁcant change
compared with 5.2mmol/L glucose containing normoglycemic
control medium (Figure 1C). Activation of IRE1 by ER stress
generates a mature XBP-1 mRNA by unconventional splicing
of XBP-1 pre-mRNA,9 and activated XBP-1 up-regulates
molecular chaperone genes, including CRYAB. All three UPR
stressors resulted in a signiﬁcant increase in CRYAB expres-
sion compared with control (Figure 1, A and B). siRNA
knockdown of IRE1a, ATF6, PERK, or CRYAB signiﬁcantly
reduced the expression of their respective proteins (Figure 2A).
siRNA knockdown of IRE1a or ATF6 both caused a signiﬁ-
cant reduction in VEGF-, high glucosee, or H2O2-induced
CRYAB expression compared with untreated controls or those
receiving scrambled siRNA (Figure 2, B and C), indicating that
these two arms of the UPR pathway are participating in
maintaining homeostasis of ER stress. A total of 25 mmol/L
mannitol was used as an osmotic control for 25 mmol/LThe American Journal of Pathology - ajp.amjpathol.orgglucose and showed no signiﬁcant change compared with 5.2
mmol/L glucose-containing normoglycemic control medium
(data not shown). PERK knockdown had no effect on CRYAB
expression (Figure 2, B and C).
Induction of ER Stress Inhibits Intracellular VEGF
Degradation and Leads to VEGF Accumulation
To verify our hypothesis that ER stress, and subsequent
up-regulation of CRYAB, prevented VEGF degradation,
we undertook Western blot analysis on cell lysates to
assess intracellular VEGF and the extent of its degradation.
Exposure to VEGF, high glucose, or H2O2 resulted in
a large increase in secreted VEGF, which was much greater
than intracellular VEGF levels (Figure 3A). In contrast,
only VEGF or high glucose led to a signiﬁcant increase in
intracellular VEGF, which presented as a 42-kDa band by
using Western blot analysis (Figure 3B). A total of 25
mmol/L mannitol, used as an osmotic control for 25 mmol/
L glucose, showed no signiﬁcant change compared with
5.2 mmol/L glucose containing normoglycemic control
medium (Figure 3A). siRNA-mediated knockdown of1417
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Figure 3 The effect of ER stress induction on
VEGF expression and intracellular VEGF degrada-
tion. Conﬂuent bovine retinal microvascular end-
othelial cell cultures were treated with 100 ng/mL
VEGF, 25 mmol/L glucose, or 200 mmol/L H2O2 for
24 hours. Cells treated with 5.2 mmol/L glucose
containing medium alone or medium supple-
mented with 25 mmol/L mannitol acted as nega-
tive controls. A: VEGF expression in the culture
medium and cell lysates was measured by ELISA.
B: The overall VEGF protein levels in cell lysates
were determined by using Western blot analysis.
When VEGF was the stressor, cells were rinsed with
PBS to remove exogenous VEGF and then incu-
bated for a further 24 hours. C: Cultures were
transfected with siRNA directed against IRE1a or
ATF6, or scrambled siRNA (scr), for 24 hours, and
the cells were then treated with 100 ng/mL VEGF
for 24 hours. The total cellular proteins were
subjected to Western blot analysis to determine
the relative ratio of full-length (FL) VEGF to VEGF
fragments (FT). D: Retinal endothelial cells were
treated with different concentrations of MG132 or
AEBSF, as indicated in the presence of 100 ng/mL
VEGF for 24 hours. The total cellular proteins were
subjected to Western blot analysis to determine
the relative ratio of FL VEGF to VEGF fragments. a-
Tubulin served as the loading control. Quantita-
tion is from a minimum of three experiments, and
the results from representative Western blot
analyses are shown. *P < 0.05, **P < 0.01. The
error bars show SEM.
Liu et aleither IRE1a or ATF6 expression in cells exposed to
exogenous VEGF resulted in a decrease in total full-length
intracellular VEGF and the appearance of VEGF frag-
ments, with a range of molecular weights compared with
scrambled siRNA control in which only full-length VEGF
was observed (Figure 3C). We next tested two putative
IRE1a inhibitors, MG132 and AEBSF.23,24 The cytotox-
icity of these compounds on retinal endothelial cells was
assessed with the Cytotoxicity Detection Kit (Roche
Applied Science), and no signiﬁcant toxicity was detected
at any of the concentrations used in this study (Table 1).
Both compounds signiﬁcantly increased the fragmentation
of VEGF in a dose-dependent manner compared with
untreated controls (Figure 3D).
Inhibition of the IRE1a or ATF6 Pathways of the UPR
Partially Inhibits VEGF-Induced in Vitro Angiogenesis
We hypothesized that inhibition of the UPR pathways or the
downstream effector, CRYAB, would reduce intracellular
VEGF and, thus, partially reduce VEGF-induced angiogenesis.1418siRNA knockdown of IRE1a, ATF6, or CRYAB resulted in
a maximal reduction of approximately 40% in tubule formation
compared with VEGF-stimulated control or cells treated with
scrambled siRNA (Figure 4, A and B). MG132 resulted in
a dose-dependent reduction in tubule formation of approxi-
mately 75% compared with VEGF-stimulated control or cells
treated with scrambled siRNA (Figure 4, A and C). AEBSF
also showed partial inhibition of tubule formation of approxi-
mately 30%, which was similar at all concentrations tested
(Figure 4, A and D).
Blocking Both the UPR Pathway and Extracellular VEGF
Has an Additive Effect on the Inhibition of in Vitro
Angiogenesis
Next, we determined if combined inhibition of extracellular
VEGF and the UPR pathway was more effective in pre-
venting in vitro angiogenesis than either treatment alone. As
anticipated, anti-VEGF antibody prevented the immediate
angiogenic effect of exogenous VEGF, whereas the UPR
inhibitors had minimal or no effect on tubule formationajp.amjpathol.org - The American Journal of Pathology
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Figure 4 The effect of inhibiting the IRE1a or ATF6 pathways of the UPR on VEGF-induced in vitro angiogenesis. Retinal endothelial cells were seeded
between two layers of Matrigel in the presence or the absence of 100 ng/mL VEGF for 48 hours. Morphometric analysis of in vitro tubule length (mm/mm2) per
microscope ﬁeld was performed. A: Representative photomicrographs of tubule formation in the presence or the absence of 100 ng/mL VEGF with siRNAs
directed against IRE1a or ATF6, MG132, or AEBSF. Medium alone or cells transfected with scrambled siRNA (scr) acted as control. Images were taken 24 hours
later. B: Subconﬂuent cells were transfected with siRNAs directed against IRE1, ATF6, or CRYAB for 24 hours before the in vitro tubule formation assay. C: Cells
were treated with different concentrations of MG132, as indicated for 24 hours before the in vitro tubule formation assay. D: Cells were treated with different
concentrations of AEBSF, as indicated for 24 hours before the in vitro tubule formation assay. Each experiment was repeated a minimum of three times. *P <
0.05, **P < 0.01. The error bars show the SEM.
Targeting the UPR Boosts VEGF Blockade(Figure 5A). However, in cells that had received prior
stimulation by VEGF, followed by either anti-VEGF anti-
body, MG132, or IRE1a siRNA 24 hours later showed
a time-dependent reduction in tubule formation of approx-
imately 40%, 60%, and approximately 75%, respectively
(Figure 5B). By contrast, a combination of anti-VEGF using
either MG132 or IRE1a siRNA resulted in 77% and 94%
inhibition of tubule formation at 24 hours after exposure
(Figure 5B).0
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The American Journal of Pathology - ajp.amjpathol.orgBlocking Both the UPR Pathway and Extracellular VEGF
Is More Effective Than Either Alone in Inhibiting
Neovascularization in the Laser-Induced CNV and OIR
Mouse Models of Angiogenesis
To conﬁrm that siRNA against IRE1a, ATF6, or CRYAB
resulted in knockdown of the respective proteins in mouse
eyes, we undertook RT-qPCR and IHC (Figure 6, A and B).
As can be seen in Figure 6A, siRNA knockdown resulted in-VEGF
G132
iRNA
24
*
*
*
urs)
Figure 5 The effect of blocking both the UPR
pathway and extracellular VEGF on in vitro angio-
genesis. A: Endothelial cells were exposed to
a combination of 100 ng/mL VEGF and a neutral-
izing antibody against VEGF, IRE1a siRNA, MG132,
or a neutralizing antibody against VEGF in the
presence of either IRE1a siRNA or MG132. B: Cells
were pre-exposed to 100 ng/mL VEGF for 24 hours
and then exposed to vehicle control, a neutral-
izing antibody against VEGF, IRE1a siRNA, MG132,
or a neutralizing antibody against VEGF in the
presence of IRE1a siRNA or MG132. After incu-
bation, cells were transferred to Matrigel and
tubule length (mm/mm2) was measured 24 hours
later. The data represent the means  SEM from
a minimum of three experiments. *P < 0.05.
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Liu et ala signiﬁcant knockdown of CRYAB, ATF6, and IRE1 by 2
days after treatment in the neural retina/RPE/choroid by
65%, 57%, and 38%, respectively, compared with scram-
bled control. To conﬁrm that knockdown of CRYAB,
ATF6, and IRE1 was occurring in the vasculature, we used
IHC. UPR proteins were strongly expressed in CNV lesions
14 days after laser injury, either untreated or receiving
scrambled siRNA, and this was associated with both retinal
vessels and surrounding tissues (Figure 6B). By contrast,
only weak immunoﬂuorescence staining for UPR proteins in
CNV lesions was observed in mice receiving intravitreal
siRNA, and there was minimal association with the vascu-
lature in these lesions.1420We next tested if inhibition of the IRE1a and ATF6 UPR
pathways would inhibit angiogenesis in vivo and if
combined inhibition was more effective than single pathway
blockade. siRNA knockdown of IRE1a, ATF6, or CRYAB
or application of pharmacological inhibitors by intravitreal
injection all signiﬁcantly reduced angiogenesis in the laser-
induced CNV and OIR models by 40% to 60% (Figures 6
and 7). A total of 5 ng per eye intravitreal injection of
anti-VEGF164 (based on a dose-response study, data not
shown) resulted in a 30% to 40% inhibition of neo-
vascularization in both models. Intravitreal injection of the
Fc fragment showed no signiﬁcant difference compared
with the vehicle control (Figure 6, C and D). In both animalajp.amjpathol.org - The American Journal of Pathology
Targeting the UPR Boosts VEGF Blockademodels, combined CRYAB siRNA and anti-VEGF treat-
ment had a signiﬁcantly greater inhibitory effect than either
treatment alone and reduced angiogenesis by at least 60%
(Figure 6, C and E, and Figure 7). Interestingly, different
UPR pathways appear to be involved in the CNV and OIR
models. IRE1a, but not ATF6, knockdown had an additive
effect with anti-VEGF treatment in the CNV model,
whereas ATF6, but not IRE1a, knockdown had an additive
effect with anti-VEGF treatment in the OIR model
(Figure 6, C and E). However, our interpretation is limited
to only counting pre-inner limiting membrane nuclei in the
OIR model, and we have not assessed the degree of vaso-
obliteration or the area associated with neovascular tufts.
Our observations were further supported by studies using
the pharmacological inhibitors, MG132 and AEBSF, which
predominantly target the IRE1a and ATF6 pathways of the
UPR, respectively. Both agents had a signiﬁcantly greater
inhibitory effect when given with anti-VEGF than either
agent alone in the CNV model and reduced angiogenesis by
at least 70% (Figure 6, D and F, and Figure 7). By contrast,
neither compound improved anti-VEGF strategies in the
OIR model.Discussion
In this study, we show the following: i) high glucose,
oxidative stress, or VEGF causes ER stress and activation of
the UPR pathway, which, in turn, increases CRYAB, ii)
siRNA knockdown of IRE1a, XBP-1, ATF6, or CRYAB
each increase VEGF degradation and reduce intracellular
VEGF levels, iii) a decrease of XBP1/IRE1a, ATF6, or
CRYAB inhibits in vitro angiogenesis and elicits a partial
reduction in angiogenesis in both the CNV and OIR models,
and iv) combination therapy blocking both the UPR and
extracellular VEGF further reduces in vitro angiogenesis
and retinal/choroidal neovascularization.Figure 6 The effect of blocking both the UPR pathway and extracellular VEGF
angiogenesis. A and B: Mice underwent the CNV model and received a 1-mL int
(scrambled siRNA was used as a control), and animals were sacriﬁced at 2 days af
**P < 0.01. A: Eyes were enucleated, and the retina plus RPE/choroid were surgica
CRYAB was determined by RT-qPCR and normalized to the housekeeping gene,
choroidal ﬂat mounts were dual stained with a vascular-speciﬁc marker, agglutin
vessels (red) and antibodies against CRYAB, ATF6, or IRE1, followed by a secon
sentative confocal microscopy images are shown, in which orange indicates coloc
images (insets) are provided to show changes in colocalization in the vasculatur
animals were terminated at 14 days after laser injury. Lesions were labeled w
rhodamine, and lesion volume was determined by confocal microscopy and image
received 1 mL of intravitreal injection of 2 mg per eye siRNAs against IRE1a, ATF6,
at laser injury. Scrambled siRNA acted as a control. D: Mice received a 1-mL intrav
absence of 5 ng of VEGF164 neutralizing antibody at laser injury. A 5 ng per eye
underwent the OIR model, and animals were terminated at P17. There was a mini
nuclei was determined per section. E: Mouse pups received a 0.5-mL intravitreal inj
or absence of 5 ng VEGF164 neutralizing antibody at P12 (immediately after be
intravitreal injection of 5 mmol/L MG132 or 50 mmol/L AEBSF in the presence or
vehicle and the appropriate Fc fragment were included as controls. *P < 0.05 vers
zP < 0.05 versus scrambled siRNA without anti-VEGF; xP < 0.05 versus ATF6 siRN
The American Journal of Pathology - ajp.amjpathol.orgThere is extensive literature reporting that ER stress and
activation of the UPR are associated with pathological
angiogenesis associated with diabetic complications, macular
degeneration, and tumors.25e29 There are a multitude of
extrinsic and intrinsic factors that can initiate the ER stress
response, leading to the accumulation of unfolded or mis-
folded proteins.30,31 Interestingly, even exogenous VEGF can
lead to an increase in unfolded/misfolded proteins in the ER
and activation of the UPR.32 The UPR pathway increases
protein maturation machinery, including molecular chaper-
ones, which are involved in the recognition, binding, solu-
bility, and refolding of proteins. These unfolded/misfolded
proteins interact with immunoglobulin binding protein BiP,
causing its release from one or more of the three ER stress
sensors, PERK, IRE1a, and ATF6, which leads to activation
of the UPR pathway(s) and the production of chaperone
proteins.9,10 The small heat shock proteins compose a class of
molecular chaperones that are characterized by their low
molecular weight (12 to 34 kDa), a conserved C-terminal
domain (the a-crystallin domain), and a helical N- and a short
ﬂexible C-terminus extension.33 One such small heat shock
protein [namely, CRYAB (HSPB5)] has been strongly
implicated in angiogenesis. First, CRYAB is signiﬁcantly
increased in tumor vessels12 and tumors grown in CRYAB/
mice are signiﬁcantly less vascularized than wild-type
tumors.15 Second, CRYAB expression is up-regulated in
both diabetic retinopathy and CNV34,35 and intraocular
angiogenesis is attenuated in CRYAB/ mice.14 Third,
CRYAB has interactive sequences for VEGF.13
Our study shows that high glucose, oxidative stress, and
VEGF (all factors associated with pathological angiogen-
esis) activate the UPR and lead to increased expression of
CRYAB. Based on siRNA knockdown, it appears that this
is facilitated by the IRE1a and ATF6 arms of the UPR, but
not the PERK. CRYAB is a soluble cytosolic protein that, in
addition to its ability to act as a molecular chaperone that
counteracts the formation of aberrantly folded polypeptideson neovascularization in the laser-induced CNV and OIR mouse models of
ravitreal injection of 2 mg per eye siRNAs against IRE1a, ATF6, or CRYAB
ter laser injury for RT-qPCR or 14 days after laser injury for IHC. *P < 0.05,
lly isolated. Total RNA was extracted, and the expression of IRE1a, ATF6, or
GAPDH. There were six mice per group. Error bars represent SEM. B: RPE/
inetetrarhodamine isothiocyanate (TRITC) conjugate, to visualize the CNV
dary antibody conjugated with ﬂuorescein isothiocyanate (green). Repre-
alization of vessels and the appropriate UPR protein. Higher-magniﬁcation
e under different conditions. C and D: Mice underwent the CNV model, and
ith vascular-speciﬁc dye, Ricinus Communis Agglutinin I, conjugated to
analysis software. There was a minimum of six animals per group. C: Mice
or CRYAB in the presence or absence of 5 ng VEGF164 neutralizing antibody
itreal injection of 5 mmol/L MG132 or 50 mmol/L AEBSF in the presence or
vehicle and an Fc fragment were included as controls. E and F: Mouse pups
mum of 12 animals per group. The average number of preretinal new-vessel
ection of 1 mg per eye siRNA against IRE1a, ATF6, or CRYAB in the presence
ing removed from the hypoxic chamber). F: Mouse pups received a 0.5-mL
absence of 5 ng of VEGF164 neutralizing antibody at P12. A 5 ng per eye
us vehicle. Data are presented as means  SEM. yP < 0.05 versus anti-VEGF;
A; {P < 0.05 versus IRE1 siRNA; kP < 0.05 versus CRYAB siRNA.
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Figure 7 Representative photomicrographs
showing the effect of UPR blockade and/or VEGF
neutralization on vascular lesion formation in the
CNV and OIR mouse models. A: Representative
photomicrographs of the vascular lesion quantiﬁed
in Figure 6, C and D. Mice underwent the CNV
model, and animals were terminated at 14 days
after laser injury. Lesions were labeled with
vascular-speciﬁc dye, Ricinus Communis Agglutinin
I, conjugated to rhodamine, and lesions were
visualized by confocal microscopy. Mice received
a 1-mL intravitreal injection of 2 mg per eye siRNAs
against IRE1a, ATF6, or CRYAB, 5 mmol/L MG132,
or 50 mmol/L AEBSF in the presence or absence of
5 ng VEGF164 neutralizing antibody at laser injury.
Scrambled siRNA (scr) acted as a control. B:
Representative photomicrographs of the vascular
lesion quantiﬁed in Figure 6, E and F. Mouse pups
underwent the OIR model, and animals were
terminated at P17. Retinal sections were prepared
and imaged. Mouse pups received a 0.5-mL intra-
vitreal injection of 1 mg per eye siRNA against
IRE1a, ATF6, CRYAB, 5 mmol/L MG132, or 50 mmol/L
AEBSF in the presence or absence of 5 ng VEGF164
neutralizing antibody at P12 (immediately after
being removed from the hypoxic chamber). Scale
bar Z 20 mm.
Liu et alor transcriptional regulators, can protect proteins from pro-
teosomal degradation and, thus, sustain their lifetime within
a cell.12 This appears to be the case for VEGF because
activation of the UPR led to an increase in intracellular
VEGF, and either siRNA or pharmacological inhibition of
the IRE1a and ATF6 pathways promoted VEGF degradation
and a major reduction in intracellular VEGF. Furthermore,
Ghosh et al13 have reported that CRYAB, in addition to
VEGF, has interactive sequences for other angiogenic factors,
such as ﬁbroblast growth factor and insulin. Thus, CRYAB
may act as a central regulator for several different intracellular
signaling pathways.
We next demonstrated that knockdown of CRYAB or its
upstream pathways elicited partial inhibition of VEGF-
induced in vitro angiogenesis. A similar response was also
observed in both the CNV and OIR mouse models of ocular
neovascularization after intravitreal application of siRNA or
pharmacological inhibitors of the UPR. Interestingly, siRNA
knockdown of the UPR pathways generally elicited a greater
inhibition than anti-VEGF neutralizing antibody (even at the
highest concentration of antibody tested) in both in vitro and
in vivo angiogenesis models. This may be, in part, due to the
concentration of test compound used; however, the UPR can,
through transcriptional control, regulate the expression of1422several growth factors, including VEGF.11,36,37 Nevertheless,
there is some debate as to which UPR pathways are involved,
and this may be cell type speciﬁc.
Based on our observations, we hypothesized that activa-
tion of the UPR and subsequent CRYAB up-regulation may
be critical in sustaining VEGF signaling, which may explain
the limited success achieved in neutralizing only extracel-
lular VEGF.12 We, therefore, co-administered a VEGF
neutralizing antibody with siRNA against UPR proteins or
putative pharmacological inhibitors of the UPR in the OIR
and CNV mouse models. Our studies conﬁrmed our
hypothesis that combination therapy to block both the intra-
cellular and extracellular pathways would be more effective
than either treatment on its own. Surprisingly, although
CRYAB knockdown was additive with VEGF neutralizing
antibody in both the OIR and CNV mouse models of neo-
vascularization, different UPR pathways appeared to be
involved, with IRE1a predominating in the CNV model and
ATF6 in the OIR model. This would agree with the view that
XBP1/IRE1a andATF6 pathways operate in parallel andmay
interact with each other on ER stress.10,30,38 However, regu-
lation of the UPR signaling pathways is complex because
IRE1a, XBP1, PERK, and ATF6 are themselves transcrip-
tionally controlled by the UPR.30ajp.amjpathol.org - The American Journal of Pathology
Targeting the UPR Boosts VEGF BlockadeWe also tested two putative pharmacological inhibitors,
MG132 and AEBSF, which we and others have shown can
inhibit the IRE1a and ATF6 pathways of the UPR (Table 1).
Both of these compounds were effective at inhibiting in vitro
and in vivo angiogenesis and acted additively with VEGF
neutralizing antibody to inhibit CNV, but not retinal neo-
vascularization, in the OIR model, thus emphasizing their
different pathogenic mechanisms. However, neither of these
compounds is speciﬁc for the UPR pathways: MG132 is
a commonly used proteasome inhibitor, and AEBSF is
a serine protease/NADPH oxidase inhibitor. Both have
previously been reported to inhibit angiogenesis, but the
mechanism was not well characterized.39,40 However, the
efﬁcacy of these compounds supports high-throughput
screening to identify small molecules with speciﬁcity for
proteins in the UPR for use in clinical studies. However,
caution should prevail because blocking the UPR outright
may be counterproductive because it facilitates cellular
homeostasis and CRYAB may offer the best target.
It is tempting to ascribe the UPR-mediated accumulation of
intracellular VEGF and sustained angiogenesis, even in the
absence of extracellular VEGF, to an intracellular VEGF
signaling pathway. An intracrine VEGF signaling pathway
has been identiﬁed in several cell types, including vascular
endothelial cells.7,41,42 Inhibition of this intracellular pathway
has been reported to promote endothelial cell apoptosis and
cannot be rescued by exogenous VEGF.7 This indicates that
the intracrine VEGF signaling can play an important role in
vascular aberrant neovascularization, as occurs in the retina
and tumors, and that the intracrine pathway can operate
independently of the classic extracellular VEGF pathway.
However, little is known about how the intracrine pathway is
regulated. Based on our observations, we postulate that
activation of the UPR and subsequent CRYAB up-regulation
may be critical in initiating the intracrine VEGF signaling
pathway. It is, thus, possible that intracrine VEGF signaling
acts as a primary intrinsic resistance to anti-VEGF therapies
and that this may explain the limited success achieved in
neutralizing only extracellular VEGF.12 Our in vitro data
provide some support for this, but it will be particularly
challenging to conﬁrm these results in vivo.
The impact of this study is extensive and far reaching,
given that cancer is a major cause of morbidity in the pop-
ulation and neovascular diseases of the eye, including the
exudative or wet form of AMD, diabetic retinopathy, and
retinopathy of prematurity, represent the leading causes of
vision impairment in developed countries. Blockade of
extracellular VEGF with ranibizumab (Lucentis) or bev-
acizumab (Avastin) can signiﬁcantly reduce ocular angio-
genesis, but unfortunately, many patients are refractory and
the inhibition of angiogenesis is not sustained.2,3,6 Although
reasonable success has been observed in the treatment of
ocular angiogenesis, the outcomes in tumor angiogenesis
have remained poor.43 The challenge, therefore, is to ﬁnd
adjunct therapies. Our study supports that inhibition of UPR
may obviate the need for as-frequent anti-VEGF injectionsThe American Journal of Pathology - ajp.amjpathol.organd lower the dose of exogenous VEGF blocker needed to act
synergistically to elicit complete regression of the vascular
lesion. Our study sets a paradigm for the development of
combination therapy to inhibit both the extracellular and
UPR-mediated VEGF pathways in the ﬁght against patho-
logical angiogenesis.
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